"IO Biotech's recent cancer vaccine trial showed some improvement but fell short of its primary study goal, leading to mixed market reactions and a slight decline in stock value. While upcoming Phase 3 results for their melanoma treatment could present a potential catalyst, the overall sentiment remains cautious, reflected in a low average sentiment score of 0.23."